Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

David Schwartz to Treatment Outcome

This is a "connection" page, showing publications David Schwartz has written about Treatment Outcome.

 
Connection Strength
 
 
 
0.201
 
  1. Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. Clin Gastroenterol Hepatol. 2022 05; 20(5):1059-1067.e9.
    View in: PubMed
    Score: 0.074
  2. Schwartz DA, Wang A, Ozbay B, Skup M, Eichner SF, Lin J, Chao J. Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement. Inflamm Bowel Dis. 2017 10; 23(10):1860-1866.
    View in: PubMed
    Score: 0.056
  3. King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005 Jan; 127(1):171-7.
    View in: PubMed
    Score: 0.023
  4. Pabla BS, Alex Wiles C, Slaughter JC, Scoville EA, Dalal RL, Beaulieu DB, Schwartz DA, Horst SN. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor a Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience. Dig Dis Sci. 2022 07; 67(7):3129-3137.
    View in: PubMed
    Score: 0.018
  5. Scoville EA, Tindle HA, Wells QS, Peyton SC, Gurwara S, Pointer SO, Horst SN, Schwartz DA, Adams DW, Freiberg MS, Gatskie V, King S, Abney LR, Beaulieu DB. Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study. PLoS One. 2020; 15(3):e0230656.
    View in: PubMed
    Score: 0.017
  6. Hunninghake GW, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R, Merchant R, Wilson J, Galvin J, Schwartz D. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994 Apr; 149(4 Pt 1):893-8.
    View in: PubMed
    Score: 0.011
  7. Dayton CS, Schwartz DA, Helmers RA, Pueringer RJ, Gilbert SR, Merchant RK, Hunninghake GW. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest. 1993 Jan; 103(1):69-73.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)